AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00625196
Drug: Vilanterol
RxNorm normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilanterol will be available as dry powder inhaler.
Trial: NCT00051012
Drug: ONTAK
RxNorm normalized name: Ontak
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00262236
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03720041
Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.
Trial: NCT03720041
Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.
Trial: NCT03720041
Drug: R2: Lenalidomide plus placebo maintenance
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.
Trial: NCT03720041
Drug: R2: Lenalidomide + ixazomib maintenance
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.
Trial: NCT00234871
Drug: trandolapril/verapamil
RxNorm normalized name: TRANDOLAPRIL/VERAPAMIL
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
Trial: NCT00234871
Drug: Lotrel (amlodipine/benazepril)
RxNorm normalized name: amlodipine / benazepril Oral Capsule [Lotrel]
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
Trial: NCT02516098
Drug: hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00873041
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Supplied as 125 mg, 250 mg and 500 mg tablets.
Trial: NCT04616183
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01007435
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab was supplied in vials.
Trial: NCT01007435
Drug: Placebo to tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo to tocilizumab was supplied in vials.
Trial: NCT01032291
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
Trial: NCT01032291
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
Trial: NCT01257230
Drug: tiotropium Respimat low dose
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP
Trial: NCT01257230
Drug: tiotropium Respimat high dose
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP
Trial: NCT04186988
Drug: Fluorine F 18 Ara-G
RxNorm normalized name: Fluorine F-18
DrugBank: Fluorine F-18 (DB13134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00974441
Drug: Divalproex Sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Extended Release Tablet
Trial: NCT01973387
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
Trial: NCT01973387
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
Trial: NCT00378625
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00946764
Drug: Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
RxNorm normalized name: imipramine
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00946764
Drug: Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
RxNorm normalized name: imipramine hydrochloride Oral Solution [Tofranil]
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01536665
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
Trial: NCT02209545
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
Trial: NCT00605098
Drug: Lopinavir / ritonavir
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
Trial: NCT00605098
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
Trial: NCT00491855
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose level 2.5 mg/kg given intravenously on day 1.
Trial: NCT00491855
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
Trial: NCT00491855
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
Trial: NCT03336801
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia on propofol alone.
Trial: NCT03336801
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia on sevoflurane alone.
Trial: NCT00369174
Drug: rosiglitazone maleate
RxNorm normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04071262
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT04071262
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT02762656
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine drip during surgery
Trial: NCT01320553
Drug: SPARC1102 I
RxNorm normalized name: I 123
DrugBank: Iodide I-123 (DB09420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC1102 I will be administered in both eyes
Trial: NCT00182052
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
Trial: NCT01293630
Drug: Ombrabulin (AVE8062)
RxNorm normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT01293630
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT01293630
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT02664649
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily
Trial: NCT00551148
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Trial: NCT00551148
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Trial: NCT00551148
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Trial: NCT00551148
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Trial: NCT05440591
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg tablets
Trial: NCT05440591
Drug: MetFORMIN 500 Mg Oral Tablet
RxNorm normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg tablets twice daily
Trial: NCT05440591
Drug: Dapagliflozin / metFORMIN Pill
RxNorm normalized name: dapagliflozin / metformin Pill
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination pill
Trial: NCT01997957
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
Trial: NCT03425006
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a JAK 1 selective small molecule inhibitor
Trial: NCT03652857
Drug: Apatinib Combined With Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
Trial: NCT01676753
Drug: Dinaciclib
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01676753
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03319563
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: normal saline 100 ml/10 cm of the wound length
Trial: NCT00022360
Drug: taurolidine
RxNorm normalized name: Taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02665351
Drug: Peramivir
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The two regimens of Peramivir were compared
Trial: NCT02356419
Drug: Recombinant erythropoietin stimulating protein
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Trial: NCT01220973
Drug: atorvastatin calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03645525
Drug: Human Umbilical Cord-derived Mesenchymal stem cell
RxNorm normalized name: ALLOGENEIC HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS
DrugBank: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells (DB15731)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
Trial: NCT03784599
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion
Trial: NCT03784599
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet
Trial: NCT00986401
Drug: Trospium Chloride (Sanctura XR®)
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: extended release, 60 mg, oral daily
Trial: NCT00986401
Drug: Metformin hydrochloride (Glucophage®)
RxNorm normalized name: metformin hydrochloride Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: immediate release, 500mg
Trial: NCT00969644
Drug: Somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: s.c injections once daily 10-30 mícrogram/kg/day
Trial: NCT00969644
Drug: Pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: s.c. injections once daily (10-15 mg/day)
Trial: NCT01184638
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-8% sevoflurane for maintaining the whole period of general anesthesia
Trial: NCT01184638
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-4 mg/kg/h of propofol during the whole period of general anesthesia
Trial: NCT00803400
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
Trial: NCT00803400
Drug: Alprazolam + Aerobic exercise
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association).
Trial: NCT03750188
Drug: ProHance
RxNorm normalized name: Prohance
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg ProHance intravenous injection
Trial: NCT03054363
Drug: Tucatinib in Combination with Palbociclib and Letrozole
RxNorm normalized name: tucatinib
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily
Trial: NCT03054363
Drug: Tucatinib in Combination with Palbociclib and Letrozole
RxNorm normalized name: tucatinib
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
Trial: NCT00142168
Drug: CC-5103 (lenalidomide)
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
Trial: NCT00142168
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
Trial: NCT01685801
Drug: Ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
Trial: NCT01685801
Drug: Placebo-matched-to-ivacaftor tablet
RxNorm normalized name: placebo Oral Tablet
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Orally every 12 hours up to 4 weeks.
Trial: NCT04345861
Drug: Hydroxychloroquine + placebo
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
Trial: NCT00201357
Drug: Thalidomide (THADO)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients who receive thalidomide (100 mg BID).